DUBLIN, Aug. 3, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its second quarter 2017 continuing operations performance.
Total net revenues were $4.0 billion, a 9 percent increase from the prior year quarter, driven by BOTOX®, JUVEDERM Collection®, the addition of ALLODERM® and CoolSculpting® and new products, including VRAYLAR™, NAMZARIC® and VIBERZI®. The increase was partially offset by lower revenues from ASACOL® HD and MINASTRIN® due to the loss of patent exclusivity, the continuing decline in NAMENDA XR® and lower revenues from RESTASIS®, which was negatively impacted by trade buying patterns in the quarter.
